| neoplasm: gallium imaging | <radiology> Useful: Hodgkin disease and histiocytic form of NHL poor sensitivity below the diaphragm, Burkitt lymphoma: almost 100% sensitivity, hepatoma: 90% sensitivity, melanoma: 90% sensitivity, leukaemia possibly useful: NHL: good for large and mediastinal lesions, nodal metastases from seminoma and embryonal cell carcinoma: 87% sensitivity, non-small cell lung CA: 85% sensitive not useful: head and neck, GI (especially adenocarcinoma), breast, gynaecological, kiddie tumours see: gallium: indications (12 Dec 1998) |
|---|---|
| neoplasm invasiveness | Ability of neoplasms to infiltrate and actively destroy surrounding tissue. (12 Dec 1998) |
| neoplasm recurrence, local | The local recurrence of a neoplasm following treatment. It arises from microscopic cells of the original neoplasm that have escaped therapeutic intervention and later become clinically visible at the original site. (12 Dec 1998) |
| neoplasm regression, spontaneous | Disappearance of a neoplasm or neoplastic state without the intervention of therapy. (12 Dec 1998) |
| neoplasm, residual | Remnant of a tumour or cancer after primary, potentially curative therapy. (dr. Daniel masys, written communication) (12 Dec 1998) |
| neoplasm seeding | The local implantation of tumour cells by contamination of instruments and surgical equipment during and after surgical resection, resulting in local growth of the cells and tumour formation. (12 Dec 1998) |
| neoplasm staging | Methods which attempt to express in replicable terms the extent of the neoplasm in the patient. (12 Dec 1998) |
| neoplasm transplantation | Experimental transplantation of neoplasms in laboratory animals for research purposes. (12 Dec 1998) |
| DNA, neoplasm | DNA present in neoplastic tissue. (12 Dec 1998) |
| drug resistance, neoplasm | Resistance or diminished response of a neoplasm to an antineoplastic agent in humans, animals, or cell or tissue cultures. (12 Dec 1998) |